Loading…
EYSANO is a brand name for Timolol. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Eysano eye drops, solution is a beta-adrenoreceptor blocking agent used topically in the reduction of elevated intra-ocular pressure in various conditions. Eysano is indicated in adult patients with ocular hypertension; adult patients with chronic open-angle glaucoma including aphakic patients; some adult patients…
Verbatim from this product's MHRA label. Tap a section to expand.
5 mg/ml solution in the affected eye, once or twice (morning and evening) a day. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic adverse reactions and an increase in local activity.
If clinical response is not adequate, dose may be changed to one drop of 5 mg/ml solution in each affected eye, once or twice (morning and evening) a day. If needed, Eysano may be used with other agent(s) for lowering intra-ocular pressure.
4). Intra-ocular pressure should be reassessed approximately four weeks after starting treatment because response to Eysano may take a few weeks to stabilise. Provided that the intra-ocular pressure is maintained at satisfactory levels, many patients can then be placed on once-a-day therapy of Eysano.
5 mg/ml Eysano in each affected eye once or twice (morning and evening) a day. The dose may be increased to one drop of 5 mg/ml solution in each affected eye once or twice (morning and evening) a day if the response is not adequate.
5 mg/ml Eysano in each affected eye once or twice (morning and evening) a day. On the following day, discontinue the previous agent completely and continue with Eysano. If a higher dose of Eysano is required, substitute to one drop of 5 mg/ml solution in each affected eye once or twice (morning and evening) a day.
Eysano eye drops, solution is a sterile solution that does not contain a preservative. Patients should be instructed to wash their hands before use and avoid allowing the tip of the container to come into contact with the eye or surrounding structures as this could cause injury to the eye.
Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
Paediatric population Due to limited data, timolol could only be recommended for use in primary congenital and primary juvenile glaucoma for a transitional period while a decision is made on a surgical approach and in case of failed surgery while awaiting further options.
Posology Clinicians should strongly evaluate the risks and benefits when considering medical therapy with timolol in paediatric patients. A detailed medical history and examination to determine the presence of systemic abnormalities should precede the use of timolol.
Summary of the safety profile Like other topically applied ophthalmic medicinal products, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta-blocking agents. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration.
The mentioned adverse reactions include reactions set within the group of ophthalmological beta-blockers. The most common adverse reactions are burning or biting sensations after instillation, which occurs in approx. 13% of the patients.
Tabulated summary of adverse reactions The following adverse reactions are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) or not known (cannot be estimated from the available data).
g. burning, stinging, itching), conjunctival hyperemia, feeling of a foreign object in the eye, secretion, conjunctivitis, blepharitis, keratitis, decreased corneal sensitivity and dry eyes, blurred vision. 4) Ear and labyrinth disorders Rare Tinnitus Cardiac disorders Uncommon Rare Bradycardia Arrhythmia, heart block, congestive heart failure, palpitations, cardiac arrest Vascular disorders Rare Hypotension, claudication, Raynaud's phenomenon Respiratory, thoracic and mediastinal disorders Uncommon Dyspnoea Rare Bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, cough Gastrointestinal disorders Uncommon Rare Nausea, dyspepsia Diarrhoea, dry mouth Skin and subcutaneous tissue disorders Rare Alopecia, psoriasiform rash or exacerbation of psoriasis Musculoskeletal and connective tissue disorders Rare Systemic lupus erythematosus Reproductive system and breast disorders Rare Peyronie's disease General disorders and administration site conditions Uncommon Rare Asthenia, fatigue Oedema, cold hands and feet, chest pain Additional adverse reactions have been seen with ophthalmic beta-blockers and may potentially occur with Eysano.
Like other topically applied ophthalmic agents, timolol is absorbed systemically. Due to beta-adrenergic component, timolol, the same types of cardiovascular, pulmonary and other adverse reactions seen with systemic beta-adrenergic blocking agents may occur.
Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. 2. Other beta-blocking agents The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol is given to patients already receiving a systemic beta-blocking agent.
The response of these patients should be closely observed. 5). In patients with closed-angle glaucoma, Eysano should be used in combination with miotics, as the immediate purpose of the treatment is to reopen the chamber angle which requires a constriction of the pupil.
Timolol has little or no effect on the pupil. g. timolol, acetazolamide) after filtration procedures. Anaphylactic reactions While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and may be unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.
g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.
Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block. e. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution. Respiratory disorders Respiratory reactions, including death due to bronchospasm in patients with asthma, have been reported following administration of some ophthalmic beta-blockers.
1. As with all products containing beta-receptor blocking agents, Eysano is contraindicated in patients with: • Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease • Sinus bradycardia, sick sinus syndrome, sino-atrial block, second- or third-degree atrioventricular (AV) block, not controlled with pace-maker • Overt cardiac failure, cardiogenic shock
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Timolol in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
1). However, if benefit outweighs the risk, it is recommended to use the lowest active agent concentration available once daily. If intra-ocular pressure (IOP) could not be sufficiently controlled, a careful up titration to a maximum of two drops of 5 mg/ml timolol eye drops solution daily per affected eye has to be considered.
If applied twice daily, an interval of 12 hours should be preferred. Furthermore, the patients, especially neonates, should be closely observed after the first dose for one to two hours in the office and closely monitored for ocular and systemic adverse reactions until surgery is performed.
Method of administration To limit potential adverse reactions only one drop should be instilled per dosing time. g. for 3 - 5 minutes) after instillation of drops. 2. Duration of treatment For a transient treatment in the paediatric population.
Immune system disorders Systemic allergic reactions including pruritus Metabolism and nutrition disorders Hypoglycaemia Eye disorders Tearing, redness, corneal erosion Cardiac disorders Heart failure Gastrointestinal disorders Dysgeusia, abdominal pain, vomiting Skin and subcutaneous tissue disorders Skin rash Musculoskeletal and connective tissue disorders Myalgia Reproductive system and breast Sexual dysfunction disorders Cases of corneal calcification have been reported very rarely in association with the use of phosphate-containing eye drops in some patients with significantly damaged corneas.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store).
Eysano should be used with caution in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk. Hypoglycaemia/diabetes Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycaemia.
Beta-blockers may also mask the signs of hyperthyroidism. Corneal diseases Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution. g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.
g. diplopia, ptosis, general weakening). • Untreated pheochromocytoma. • Metabolic acidosis. • Large surgical procedures: It is recommended to gradually decrease the use of adrenergic beta-blocking medicinal products prior to the procedure in order to avoid the reflex stimuli of the beta-blockers on the heart and thus lessen the risk of hypotension and cardiac arrest during the anaesthesia.
• Intermittent claudication. • Severely reduced kidney function. With dialysis patients, pronounced drop in blood pressure has been observed. Patients with a history of contact hypersensitivity to silver should not use this product as dispensed drops may contain traces of silver.
Timolol has not been studied in patients using contact lenses. Eysano should not be used while using soft contact lenses. The lenses should only be inserted 15 minutes after the drip. 2). 8). Signs to look for are, for example, coughing and wheezing.
Because of the possibility of apnoea and Cheyne-Stokes breathing, the medicinal product should be used with extreme caution in neonates, infants and toddlers. A portable apnoea monitor may also be helpful for neonates on timolol.